Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in marmara university hospital


YUMUK P., ABACIOGLU U., CAGLAR H., Gumus M., SENGOZ M., TURHAL N.

JOURNAL OF CHEMOTHERAPY, vol.15, no.6, pp.603-606, 2003 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 6
  • Publication Date: 2003
  • Doi Number: 10.1179/joc.2003.15.6.603
  • Journal Name: JOURNAL OF CHEMOTHERAPY
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.603-606

Abstract

Adjuvant chemoradiotherapy is the standard treatment in resected stage II/III rectosigmoid carcinoma. We report a retrospective analysis of 33 patients who received adjuvant chemoradiotherapy. Patients received 5-fluorouracil (375mg/m(2)/day x 5days) and calcium leucovorin (20mg/m(2)/day x 5days), q4weeks, two courses before and two courses after radiotherapy. The 5-fluorouracil dose was reduced to 225mg/m(2)/day given continuously as protracted short-term infusion on the first and last 3 days during radiotherapy. Radiotherapy was started at 7th week and 45-50.4 Gy was given to pelvic region. Median age was 63 years. Median follow-up was 38 months starting from the operation date. Four-year local and distant control rates were 78% and 69%, respectively. Four-year disease-free survival and overall survival were 60% and 62%, respectively. Protracted short-term infusion of 5-fluorouracil during pelvic irradiation is a safe treatment modality. Further studies are needed to improve the local control of high-risk rectal and sigmoid carcinomas.